Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;75(4):e13847.
doi: 10.1111/ijcp.13847. Epub 2021 Jan 21.

Shifting the treatment paradigm in idiopathic overactive bladder

Arun Sahai  1 , Mo Belal  2 , Rizwan Hamid  3 , Phillip Toozs-Hobson  4 , Paraskeve Granitsiotis  5 , Dudley Robinson  6
Affiliations
Review

Shifting the treatment paradigm in idiopathic overactive bladder

Arun Sahai et al. Int J Clin Pract. 2021 Apr.

Abstract

Purpose: Overactive Bladder (OAB) is a common condition that is known to have a significant impact on Health Related Quality of Life (HRQoL). Whilst all patients will initially benefit from lifestyle modifications and behavioural therapy in the first instance drug therapy remains integral in management pathways. The purpose of this review paper is to reappraise the evidence based approach to the management of OAB in addition to exploring a new treatment algorithm for the escalation of treatment in those patients with refractory symptoms.

Design: Literature Review RESULTS: Antimuscarinic drugs are currently the most commonly used medication although the introduction of mirabegron, a β3 agonist, has provided an alternative and also allowed combination therapy in those patients who have failed to improve on primary therapy or who have troublesome side effects. For those patients with symptoms of refractory OAB more invasive therapies including OnabotulinumtoxinA, sacral neuromodulation and Percutaneous Tibial Nerve Stimulation (PTNS) may be indicated.

Conclusion: We propose a new, evidence based, treatment algorithm for the management of OAB in patients who remain refractory to first line therapy.

PubMed Disclaimer

References

REFERENCES

    1. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynaecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5-26.
    1. International Continence Society. www.ics.org. Accessed July 30, 2020
    1. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? Urology. 2006;175:191-195.
    1. Hamid R, Loveman C, Millen J, et al. A cost-effectiveness analysis of onabotulinumtoxina versus best supportive care (BSC) for the treatment of anticholinergic treatment -refractory neurogenic detrusor overactivity (NDO). Value Health. 2014;17:A470 [Abstract PUK21].
    1. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388-1395.

LinkOut - more resources